Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma

BACKGROUND: Whether immunotherapy combined with different histone deacetylases (HDAC) inhibitors in refractory or relapsed natural killer/T-cell lymphoma (NKTCL) is superior to each agent is still lacking in head-to-head clinical trials or preclinical evidence. METHODS: NKTCL cell line xenograft mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Tingyu, Sun, Guangyi, Jiang, Wenxin, He, Xiaohui, Shi, Yuankai, Ma, Fei, Liu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823149/
https://www.ncbi.nlm.nih.gov/pubmed/36592514
http://dx.doi.org/10.1016/j.ebiom.2022.104420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823149/
https://www.ncbi.nlm.nih.gov/pubmed/36592514
http://dx.doi.org/10.1016/j.ebiom.2022.104420

Ejemplares similares